Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral fluorescent tracer administration for early esophageal adenocarcinoma detection in Barrett's esophagus
NL-OMON59218Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab-IRDye800CW and cetuximab-IRDye 800CW in Barrett's esophagus and esophageal adenocarcinoma (EAC) (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Feasibility of oral tracer administration, Safety of oral tracer administration and 1 more. Started Sep 2023; status: completed.
02
Drugs
bevacizumab-IRDye800CWcetuximab-IRDye 800CW
03
Conditions
Barrett's esophagusesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON59218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59218.